N-acetylcysteine Increases the Frequency of Bone Marrow Pro-B/pre-B Cells, but Does Not Reverse Cigarette Smoking-induced Loss of This Subset
Overview
Authors
Affiliations
Background: We previously showed that mice exposed to cigarette smoke for three weeks exhibit loss of bone marrow B cells at the Pro-B-to-pre-B cell transition, but the reason for this is unclear. The antioxidant N-acetylcysteine (NAC), a glutathione precursor, has been used as a chemopreventive agent to reduce adverse effects of cigarette smoke exposure on lung function. Here we determined whether smoke exposure impairs B cell development by inducing cell cycle arrest or apoptosis, and whether NAC treatment prevents smoking-induced loss of developing B cells.
Methodology/principal Findings: Groups of normal mice were either exposed to filtered room air or cigarette smoke with or without concomitant NAC treatment for 5 days/week for three weeks. Bone marrow B cell developmental subsets were enumerated, and sorted pro-B (B220(+)CD43(+)) and pre-B (B220(+)CD43(-)) cell fractions were analyzed for cell cycle status and the percentage of apoptotic cells. We find that, compared to sham controls, smoke-exposed mice have ∼60% fewer pro-B/pre-B cells, regardless of NAC treatment. Interestingly, NAC-treated mice show a 21-38% increase in total bone marrow cellularity and lymphocyte frequency and about a 2-fold increase in the pro-B/pre-B cell subset, compared to sham-treated controls. No significant smoking- or NAC-dependent differences were detected in frequency of apoptotic cells or the percentage cells in the G1, S, or G2 phases of the cycle.
Conclusions/significance: The failure of NAC treatment to prevent smoking-induced loss of bone marrow pre-B cells suggests that oxidative stress is not directly responsible for this loss. The unexpected expansion of the pro-B/pre-B cell subset in response to NAC treatment suggests oxidative stress normally contributes to cell loss at this developmental stage, and also reveals a potential side effect of therapeutic administration of NAC to prevent smoking-induced loss of lung function.
Implications of the Immune Landscape in COPD and Lung Cancer: Smoking Versus Other Causes.
Taucher E, Mykoliuk I, Lindenmann J, Smolle-Juettner F Front Immunol. 2022; 13:846605.
PMID: 35386685 PMC: 8978964. DOI: 10.3389/fimmu.2022.846605.
Strzelak A, Ratajczak A, Adamiec A, Feleszko W Int J Environ Res Public Health. 2018; 15(5).
PMID: 29883409 PMC: 5982072. DOI: 10.3390/ijerph15051033.
Impacts of cigarette smoking on immune responsiveness: Up and down or upside down?.
Qiu F, Liang C, Liu H, Zeng Y, Hou S, Huang S Oncotarget. 2016; 8(1):268-284.
PMID: 27902485 PMC: 5352117. DOI: 10.18632/oncotarget.13613.
Messier E, Day B, Bahmed K, Kleeberger S, Tuder R, Bowler R Am J Respir Cell Mol Biol. 2013; 48(5):559-67.
PMID: 23492188 PMC: 3707381. DOI: 10.1165/rcmb.2012-0295OC.
B cells and antibodies in multiple sclerosis pathogenesis and therapy.
Krumbholz M, Derfuss T, Hohlfeld R, Meinl E Nat Rev Neurol. 2012; 8(11):613-23.
PMID: 23045237 DOI: 10.1038/nrneurol.2012.203.